Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

Aman U. Buzdar, George R. Blumenschein, Terry L. Smith, Charles K. Tashima, Gabriel N. Hortobagyi, H. Yong Yap, Jordan U. Gutterman, Evan M. Hersh, Edmund A. Gehan

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

A combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01). Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.

Original languageEnglish (US)
Pages (from-to)27-40
Number of pages14
JournalJournal of Surgical Oncology
Volume12
Issue number1
DOIs
StatePublished - 1979

Keywords

  • adjuvant chemotherapy
  • isolated recurrence of breast cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)'. Together they form a unique fingerprint.

Cite this